ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer’s Disease

September 13, 2017 07:30 ET | Source: ProMIS Neurosciences Inc. ProMIS Neurosciences Inc.

TORONTO and CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- ERN UK

Recommended Reading

December 10, 2025 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS on track to complete enrollment in PRECISE-AD trial...
Read More
December 01, 2025 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ PRECISE-AD trial ProMIS on track to leverage new...
Read More